The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

Similar to its competitors, Pfizer also plans to partner with a Chinese company. The company PFE announced late Monday a license agreement with China-based 3SBio Inc. HK:1530 to develop ...

(Reuters) -U.S. stock index futures were subdued on Tuesday as investors awaited the outcome of a second day of trade talks ...

Ireland previously made the list in 2019 and 2021, but has returned as Donald Trump promises to clamp down on allegedly ...

Pfizer reported a strong sales performance for its antifungal drug Cresemba in the Asia Pacific and China, thanks to a ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

Chinese drug maker 3SBio has licensed its new cancer drug to US pharmaceutical giant Pfizer in the largest deal ever for China’s biotech industry, underscoring the strong commercial Sino-US ties ...

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer has announced a new agreement to develop and market a cancer drug being developed by Chinese drugmaker 3SBio.